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ihe epidemiology of mesothelioma first came to light in
1960 with the report by Wagner and colleagues of 33
sbestos mine workers from South Africa who developed
esothelioma.1 Malignant pleural mesothelioma (MPM) is a
are tumor but the geographical distribution of the disease is
iverse; taken as a whole, the United States has an incidence
ust under 1 per 100,000. However, the incidence has been
ising since the 1970s. The male-to-female ratio is 5:1, which
s likely due to the occupational exposure of asbestos.
Staging in MPM, as is the case in other aspects of the disease,
acks consensus. Various staging systems exist. The classic sys-
em described by Butchart and colleagues in 1976 is relatively
imple anddescriptive.2 The Brigham staging system is based on
esectability by extrapleural pneumonectomy (EPP) and may
ot be of value in patients undergoing pleurectomy and decor-
ication (P/D). The TNM staging system proposed by the Inter-
ational Mesothelioma Interest Group (IMIG) is the most com-
rehensive and is accepted by theAmerican Joint Committee on
ancer (AJCC) and InternationalUnionAgainstCancer (UICC).
ndications for Surgery
PM was thought to be uniformly fatal in the days before
ffective systemic therapy. Surgery was reserved for diag-
osis and palliation. In the first reports of “curative” sur-
ery, Butchart and colleagues (1976) performed EPP with
surgical mortality of 30%.2 In the nearly 30 years since
he initial report, advances in patient selection and intra-
perative and postoperative management have substan-
ially decreased the mortality of the operation as reported
y centers with high volumes of mesothelioma surgery.
ugarbaker and colleagues reported their mortality from
28 consecutive EPP performed at the Brigham and Wom-
n’s Hospital as 3.4%.3 At Memorial Sloan-Kettering, we
eported a 5.2% mortality for EPP. The staggeringly high
ortality seen in early attempts at EPP led to a movement
way from this operation and toward P/D. The mortality of
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oi:10.1053/j.optechstcvs.2006.02.002/D is reported as l.8% and the lack of evidence demon-
trating superiority of EPP over P/D was thought to be due
o the up-front mortality increase with the more extensive
peration.
There are those who still believe that surgical intervention
or purposes other than palliation in mesothelioma is not
ndicated. While it is true that there are no randomized con-
rolled trials comparing surgical treatment to supportive care,
he reality is that these trials will likely never be performed.
or those who treat this disease and have a less nihilistic
utlook, surgery forms a key component of the treatment
lgorithm.
ndications for P/D
ndications for P/D can be thought of as being patient related
r tumor related. Perhaps the least controversial statement
ne can make about P/D is that it can be offered to patients
ho do not have the cardiopulmonary reserve to tolerate
neumonectomy. For patients who can tolerate pneumonec-
omy, the choice of operation becomes less clear. Some cen-
ers perform P/D for patients with early-stage disease, con-
ned to the parietal pleural “capsule” (Butchart I, IMIG T1a,
r T1b), the reasoning being that if no lung parenchyma is
nvolved the inherent morbidity and mortality risk of adding
pneumonectomy is not warranted. Others disagree, feeling
hat the absence of lung parenchyma facilitates the adminis-
ration of postoperative adjuvant radiotherapy.
If one accepts that MPM is a disease where true R0
esections are a theoretical achievement, then the goal of
urgery is to remove all gross tumor and serve as a foun-
ation for adjuvant therapy. The choice of operation can
hen be made based on the extent of resection required
nd the extent of resection that the patient will tolerate.
ome clinicians feel that with newer methods of radiation
dministration and ongoing attempts at other local and
ystemic therapies, the argument that residual lung paren-
hyma hinders appropriate adjuvant therapy may be less
f a factor than it once was.
reoperative Evaluation
ll patients undergoing consideration for P/D need thorough
maging and cardiopulmonary evaluation. At a minimum,
ulmonary function testing should be performed. Quantita-
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58 R.M. Flores and N. Alamive ventilation perfusion scans may also be indicated if asso-
iated lung resections are anticipated or to evaluate the pos-
ibility of EPP. Computed tomography of the thorax and
pper abdomen is required imaging and magnetic resonance
magingmay be superior in assessing discrete focuses of chest
all invasion or diaphragmatic muscle involvement but
arely changes surgical decisions.4 18Fluorodeoxyglucose
ositron Emission Tomography (FDG-PET) scanning in
PM can be used to provide stage and prognostic informa-
ion. In addition to helping to determine the extent of tumor,
ET can be used to detect N3 or M1 disease in 10% of pa-
ients.5,6 The standardized uptake value (SUV) can also be tsed to predict the presence of N2 lymphatic spread.6 High
UV has also been shown to correlate with poor survival in
PM.7
Another controversial question in the preoperative evaluation
f patients is the role of mediastinoscopy in MPM. It is useful in
etermining the N-stage of most patients and is more accurate
han computed tomography. However, up to 25% of patients
ave lymphnode involvement confined to areas of the hemitho-
ax inaccessible by mediastinoscopy such as the peridiaphrag-
atic or internal mammary regions. Furthermore, although N2
isease does negatively impact survival, it should not be used as
he sole criteria to deny someone surgery.
Treatment of malignant pleural mesothelioma 59Operative Technique
Figure 1 Patient in the lateral decubitus position. Following the induction of general anesthesia, a double lumen
endotracheal tube should be inserted to facilitate the operation. An arterial line and central venous pressure monitoring
are important as blood loss is often significant. The patient is placed in the lateral decubitus position and an extended
posterolateral thoracotomy incision extending downwards to the costal margin is made.
60 R.M. Flores and N. AlamFigure 2 Sixth rib removed. The sixth rib is resected and the dissection is begun in the plane between the endothoracic
fascia and the parietal pleura. The pleural tumor is bluntly dissected away from the chest wall.
Treatment of malignant pleural mesothelioma 61Figure 3 Dissection of the extrapleural plane. The plane is then developed in a cephalad direction toward the apex from
the posterolateral direction using blunt and sharp dissection.
62 R.M. Flores and N. AlamFigure 4 Exposure of extrapleural thoracic cavity is facilitated by the placement on two finnechetto retractors. After a
sufficient area of chest wall has been mobilized, two chest retractors facilitate exposure. Care in identifying the
subclavian vessels is prudent as a traction injury to these structures is difficult to repair. As each area of dissection is
completed, packs are placed to aid in hemostasis as a fair amount of blood loss will result from the blunt dissection. The
dissection is then continued inferior and posterior from the incision to the diaphragm.
Treatment of malignant pleural mesothelioma 63Figure 5 (A) Superior dissection of subclavian artery and aortic arch. (B) Superior dissection of SVC and azygous vein.
The pleura can now be mobilized from the mediastinum. Once the upper portion of the lung is completely mobilized
from the chest wall, the superior and posterior hilar structures are well exposed. On the left side, the esophagus and
aorta must be identified and the dissection around them undertaken with care (A). On the right side, the superior vena
cava must be dissected away from the specimen gently (B). The dissection then continues to the posterior aspect of the
pericardium. SVC  superior vena cava.
64 R.M. Flores and N. AlamFigure 5 Continued
Treatment of malignant pleural mesothelioma 65Figure 6 (A) Lateral dissection of descending aorta and esophagus. (B) Lateral dissection of carina and esophagus. On
the left, care must be taken not to injure the descending aorta (A). On the right, a nasogastric tube helps to identify the
esophagus by palpation (B). A plane between the mediastinal pleura and the pericardium is sometimes present. If it is
not, the pericardium needs to be resected en bloc at a later stage of the operation with subsequent reconstruction.
66 R.M. Flores and N. AlamFigure 6 Continued
Treatment of malignant pleural mesothelioma 67Figure 7 Diaphragmatic fibers are cauterized while the inferior portion of the specimen is retracted cephalad. The
dissection is then carried toward the posterior diaphragmatic sulcus. If superficial involvement of the diaphragm is
found, a partial thickness resection can be performed. The plane between the tumor and the uninvolved diaphragm can
be entered and the dissection is initiated at the posterior costophrenic angle and carried anteriorly. This is facilitated by
strong retraction on the pleura away from the diaphragm. In many patients deeper involvement of the diaphragm
mandates a full-thickness resection of a portion of the muscle. The deep border of the diaphragm must then be
dissected from the peritoneum. Care should be taken to avoid entering the abdomen as tumor seeding into the
peritoneal cavity is a concern. This is often unavoidable, especially around the central tendon, and any defect in the
peritoneum should be closed immediately. The specimen is then mobilized en bloc back toward the pericardium
medially. If resection of the pericardium is required, it is delayed until the tumor is mobilized as much as possible due
to the accompanying arrhythmias from manipulation. The pericardium is gradually opened and traction sutures are
placed on the nonspecimen edge tomaintain the position of the heart and prevent retraction of the pericardium into the
opposite hemithorax.
68 R.M. Flores and N. AlamFigure 8 Visceral pleura is separated from the underlying lung by sharp and blunt dissection. Once the dissection is
completed to the hilar structures, the parietal pleura is opened and the pleural envelope is entered and decortication of
the visceral pleura from the underlying lung and hilar vessels is performed.
Treatment of malignant pleural mesothelioma 69Figure 9 (A) Sharp and blunt dissection separates lobes. (B) Sharp dissection to remove visceral pleura tumor off
fissures. (C) Careful dissection of pleura from underlying pulmonary artery. This is, in some respects, the most
technically demanding and tedious component of the operation. Decortication must be performed with care into the
fissures because they are often substantially involved with disease. During the decortication, deflation of the lung will
minimize blood loss and inflation will allow better visualization of the plane between the tumor and the visceral pleura
or lung parenchyma. Communication with the anesthesiologist about the amount of blood loss is important as patients
most often require intraoperative transfusion.
Lymph node dissection should be performed and specimens sent and labeled separately to the pathologist. The
subcarinal lymph nodes should be resected as well as the paratracheal lymph nodes on the right and aorto-pulmonary
lymph nodes on the left.
70 R.M. Flores and N. AlamFigure 9 Continued
Treatment of malignant pleural mesothelioma 71Figure 9 Continued
72 R.M. Flores and N. AlamFigure 10 If enough diaphragm remains, it is usually defunctionalized and requires plication. Once the gross tumor is
removed and the specimen is delivered, reconstruction of the pericardium and diaphragm, if required, are performed.
If the diaphragm is largely intact, it can be closed primarily by plication to prevent upward movement and subsequent
compression atelectasis of the lower lobe. On the right side, reconstruction of the diaphragm is performed with a
double layer of Dexon mesh as the liver prevents herniation of intraabdominal contents. On the left, 2-mm-thickness
Gore-Tex is used because thicker nonabsorbable material is required to prevent herniation. The prosthesis is secured
laterally by placing sutures around the ribs. Posteriorly it is sutured to the crus or tacked to the prevertebral fascia. The
medial aspect is sewn to the remaining edge of the diaphragm at its confluence with the pericardium. The diaphrag-
matic prosthesis should be made absolutely taut to prevent upward motion of the abdominal contents and subsequent
atelectasis of the lower lobe. If the pericardium was resected, it is reconstructed with a single layer of Dexon mesh.
Attention is now turned to obtaining hemostasis. An argon beam electrocoagulator may be used to help control
diffuse bleeding from the chest wall. Three chest tubes are placed anteriorly and posteriorly into the apex and a right
angle tube along the diaphragm. This should allow for control of the substantial air leaks that are anticipated and permit
full expansion of the lung. The air leaks tend to resolve after 72 hours if the lung is fully expanded.
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Treatment of malignant pleural mesothelioma 73itfalls
uring the dissection, certain areas of particular concern
arrant special mention. The subclavian vessels can be in-
ured by traction during the blunt dissection of the apex. On
he right, care needs to be taken in the dissection of the
ediastinal pleura from the superior vena cava. On the left,
he plane between the tumor and the adventitia of the aorta,
he origins of the intercostal vessels, and the esophagus,
hould all be identified.
If the diaphragm is largely left intact and reconstruction is
ot undertaken, plication is often helpful to prevent elevation
nd paradoxical motion of the diaphragm and atelectasis of
he lower lobe.
While prior talc pleurodesis is not an absolute contraindi-
ation to the operation, it does increase the likelihood of
ubstantial blood loss and air leak.
esults
/D is generally well tolerated with a mortality limited to
pproximately 1 to 2% when performed at high volume cen-
ers. The most common complication is prolonged air leak
ccurring in 10% of patients. Hemorrhage, pneumonia, and
mpyema are less common complications. Median survivals
or P/D alone range from 9 to 20 months in the literature.
The technical challenge of separating tumor and visceral
leura from the lung parenchyma may result in suboptimal
ytoreduction. This is reflected in the observation that the
ost common site of recurrence is the ipsilateral hemitho-
ax.8
ombined Modality Therapy
ince the results of surgery alone are poor, most recent stud-
es have combined P/D with some form or combination of
djuvant therapy. These have included external radiation,
rachytherapy, systemic chemotherapy, intrapleural chemo-
herapy, and photodynamic therapy. It is important to note
hat these studies are almost uniformly observational in na-
ure.When comparisons are performed, they are by and large
cross inhomogeneous groups, thereby limiting the conclu-
ions that can be drawn about efficacy.
/D with Radiation
tudies have used various forms of radiation therapy. The
arliest experience with combined therapy for MPM was re-
orted by McCormack and coworkers, at Memorial Sloan-
ettering Cancer Center (MSKCC).9 The combination of P/D
ith external radiation and systemic chemotherapy in 18
atients with epithelial mesothelioma produced a median
urvival of 16months. In the subsequent 33 patients, brachy-
herapy was added and the median survival was 21 months.
In another study at MSKCC, brachytherapy was used in
atients following P/D who had gross residual disease fol-
owed by postoperative external beam radiation therapy (me-
ian dose of 4200 cGy). Local failure or disease progression
ccurred in 63% of patients and median survival was 13
onths. Alberts and coworkers evaluated 262 patients with
PM, 26 of whom had P/D followed by radiation and che-
otherapy.10 The median survival for the whole group was M.6 months and for the subset undergoing surgery was 10.9
onths, which was not a statistically significantly difference.
A Finnish study comprising 100 patients evaluated five
ifferent adjuvant radiation schedules and chemotherapy
egimens following pleurectomy.11 The median survival was
months and the 2-year survival was 20%. They found no
ifference among the groups.
In a more recent study, Lee and colleagues fromUniversity
f California, San Francisco reported their experience with
2 patient who had undergone P/D with intraoperative ra-
iotherapy followed by external beam radiation.12 Some pa-
ients received chemotherapy as well. The median survival of
he 26 patients who underwent the planned treatment was
8.1 months. Not included in the analysis are the three pa-
ients who had unresectable disease, one patient with recur-
ent disease, and two patients who had early postoperative
eaths.
In patients deemed unfit for EPP who get P/D at MSKCC,
ur current practice is to give adjuvant external beam radia-
ion therapy.
/D with Intrapleural
nd/or Systemic Chemotherapy
usch and colleagues from MSKCC evaluated P/D followed
y intrapleural cisplatin andmitomycin followed by systemic
isplatin and mitomycin given 3 to 5 weeks postopera-
ively.13 There were 28 patients who underwent P/D and
eceived intrapleural chemotherapy. There was one postop-
rative death and two patients who developed grade 4 neph-
otoxicity. The median survival was 18 months and signifi-
ant morbidity was present in 53% of patients. Local failure
as high with 16 local relapses in 27 patients. The authors
ere concerned about the potential for serious toxicity.
Rice and coworkers studied 19 patients who had EPP (n
0) or P/D (n 9) followed by intrapleural administration of
isplatin and mitomycin in patients with stage I MPM.14 The
edian survival was 13 months and the treatment-related
ortality was 5%.
A group from UCLA reported their results of 15 patients
ho underwent P/D followed by intrapleural cisplatin and
ytarabine.15 The median survival was 11.5 months with no
reatment-related mortality. A similar study was reported by
n Italian group who added systemic chemotherapy to the
ame regimen of P/D and intrapleural chemotherapy.16 Their
0 patients also had an 11.5-month median survival.
A group from Turkey reported on 20 patients who had P/D
ollowed by systemic chemotherapy consisting of cisplatin,
itomycin, and -interferon immunotherapy.17 The median
urvival was 12 months and the regimen was well tolerated.
In a more recent study, Ceresoli and colleagues from Italy
etrospectively reviewed their experience with MPM and
oted that the 16 patients that had P/D followed by chemo-
herapy did better than patients who received P/D or chemo-
herapy alone.18 The median survivals were 14 months in the
ombined treatment group, 12 months in the surgery alone
roup, and 8 months in the chemotherapy alone group. In
nivariate analysis treatment modality had independent
rognostic value.
The search for effective therapies to achieve local control in
PM has sparked interest in a number of areas. Hyperther-
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74 R.M. Flores and N. Alamia has been investigated in combination with surgery. Carry
nd coworkers reported the results of three patients with
PM who were given hyperthermic intrapleural mitomycin
t 42.6°C following P/D for 60 minutes.19 The technique was
eemed safe.
In a similar design, Ratto and coworkers gave hyperther-
ic cisplatin (41.5°C) for 60 minutes following P/D (three
atients) or EPP (four patients).20 Patients also received 55
y to chest wall incisions. There was no death or toxicity and
he treatment was well tolerated. An interesting finding was
hat systemic cisplatin levels were significantly higher in the
roup that had P/D, indicating that the remaining lung plays
n important role in the absorption of intrapleural cisplatin.
A group from the Netherlands studied the use of intrapleu-
al hyperthermic (40 to 41°C) cisplatin and doxorubicin fol-
owing P/D.21 There was considerable toxicity withmorbidity
eported in 47% of patients. The 11 patients had a median
urvival of 8 months. This group used the same protocol for
dvanced thymoma patients.
In a dose escalation study, Sugarbaker and colleagues per-
ormed P/D on 44 patients followed by intraperitoneal and
psilateral hemithoracic lavage with cisplatin at 42°C.22 They
eported postoperative mortality of 11% andmedian survival
f 9 months.
/D and Photodynamic Therapy
everal studies evaluated the use of photodynamic therapy
PDT), a new modality used to enhance local control.23,24 A
hotosensitizer is administered systemically and then target
reas are illuminated with laser to affect cell kill. Moskal and
oworkers from Roswell Park reported their series of 40 pa-
ients who had been treated with EPP (n 7), P/D (n 28),
r P/D with lobectomy (n 5) followed by PDT.24 Mortality
as 6.5%, with two of the deaths in the EPP group. Serious
omplications arose in 48.3% of patients. The median sur-
ival was 15 months.
Pass and colleagues at the National Institutes of Health
erformed a randomized study of surgical resection, postop-
rative cisplatin, interferon, and tamoxifen with or without
DT.23 Twenty-five patients received PDT (11 P/D and 14
PP) and 23 patients did not (12 P/D and 11 EPP). The
roups were similar and no survival difference was noted.
edian survivals in the PDT group and non-PDT group were
4.4 and 14.1 months, respectively. The conclusion was that
here was no value of first-generation PDT when added to
ultimodality therapy. Further studies with newer photo-
ensitizers and increasing light doses are ongoing.
onclusions
he role of surgery in the management of MPM remains
ontroversial. The range of goals of surgery include diagno-
is, palliation of symptoms, debulking of tumor, and possibly
ure. All these goals have been cited at one time or another by
ne group of surgeons or another as the main focus of their
articular surgical intervention. The major approaches in the
rmamentarium of the mesothelioma surgeon are thoracos-
opy for biopsy and pleurodesis, partial pleurectomy, radical
leurectomy and decortication, and extrapleural pneumo-
ectomy. With no set standards of care or overwhelming 2vidence to guide the thoracic surgeon, a fair amount of
linical judgment and a frank discussion of goals with the
atient and other members of the health care team are re-
uired to formulate a comprehensive treatment plan. How-
ver, it is clear that a multimodality approach is required.
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